Unveiling the Potential of Civil Briquette Furnace Slag as a Silico–Aluminon Additive in Alkali-Activated Materials
Abstract
Civil briquette furnace slag (FS), as a type of industrial solid waste, is not currently being recycled as a resource by the building materials industry. This study focuses on the potential of FS in the formulation of alkali-activated materials (AAMs) compared with calcium carbide slag (CS). This study encompasses three distinct AAM systems: alkali-activated fly ash alone (AAFA), fly ash–slag powder blends (AAFB), and slag powder alone (AABS). Electrical conductivity, fluidity, drying shrinkage, and flexural and compressive strengths were also assessed. Advanced characterization techniques, including SEM-EDS, XRD, FTIR, and TG-DSC, were utilized to examine the morphology, mineralogy, and reaction products. Despite the chemical similarity between FS and CS, FS exhibits limited active chemical components (SiO2, Al2O3, CaO, and MgO) and primarily functions as a physical filler, and thus lacks the chemical binding properties of CS. FS has a positive effect on the long-term compressive strength of the AABS system but not on the AAFA and AAFB systems. The NaOH-activated SP mortar sample with 20% FS reaches a compressive strength of 29.8 MPa at 360 days. The binding strength in AAMs incorporating FS is predominantly attributed to the gel formation within the alkali-activated matrix. This research offers valuable insights into the strategic use and substitution of CS, FS, and other silico–aluminon additives within the context of AAMs development.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.